Responses
Epidemiology/Health services research
Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study
Compose a Response to This Article
Other responses
No responses have been published for this article.